血管生成因子在白血病发展中的研究进展。
The progress of angiogenic factors in the development of leukemias.
作者信息
Han Yang, Wang Xidi, Wang Bingping, Jiang Guosheng
机构信息
Key Laboratory for Rare & Uncommon Diseases of Shandong Province, Institute of Basic Medicine, Shandong Academy of Medical Sciences, Ji'nan, Shandong, China; School of Medicine and Life Sciences, Ji'nan University, Ji'nan, Shandong, China.
Laboratory Department, People's Hospital of Zhangqiu City, Zhangqiu, Shandong, China.
出版信息
Intractable Rare Dis Res. 2016 Feb;5(1):6-16. doi: 10.5582/irdr.2015.01048.
Abstract
Angiogenic factors have been demonstrated to play important roles in modulating angiogenesis of solid tumors. Recently, accumulating studies extensively indicated that some angiogenic factors widely exist in malignant cells of hematologic malignancy, which regulated the expression of a number of genes that were involved in abnormal proliferation, differentiation and apoptosis of these cells. With deep research of angiogenic factors, its expression, function and regulatory mechanism were gradually elucidated, and some of them were related to the development and prognosis of leukemia, or provide more possible strategies for treatment of patients with leukemia. Herein, we summarize the progress in study of some important angiogenic factors and hematological malignancies.
摘要
血管生成因子已被证明在调节实体瘤的血管生成中发挥重要作用。最近，越来越多的研究广泛表明，一些血管生成因子广泛存在于血液系统恶性肿瘤的恶性细胞中，它们调节了许多与这些细胞异常增殖、分化和凋亡相关的基因的表达。随着对血管生成因子的深入研究，其表达、功能和调控机制逐渐得以阐明，其中一些与白血病的发生发展及预后相关，或为白血病患者的治疗提供了更多可能的策略。在此，我们总结了一些重要血管生成因子与血液系统恶性肿瘤的研究进展。
相似文献
1
The progress of angiogenic factors in the development of leukemias.血管生成因子在白血病发展中的研究进展。
Intractable Rare Dis Res. 2016 Feb;5(1):6-16. doi: 10.5582/irdr.2015.01048.
2
The progress of early growth response factor 1 and leukemia.早期生长反应因子1与白血病的研究进展
Intractable Rare Dis Res. 2016 May;5(2):76-82. doi: 10.5582/irdr.2015.01049.
3
Targeting the vascular endothelial growth factor in hematologic malignancies.针对血液系统恶性肿瘤的血管内皮生长因子。
Eur J Haematol. 2012 Nov;89(5):373-84. doi: 10.1111/ejh.12009. Epub 2012 Sep 20.
4
Mechanism and Function of Angiogenin in Hematopoietic Malignancy.血管生成素在血液系统恶性肿瘤中的作用机制及功能
Zhongguo Sheng Wu Hua Xue Yu Fen Zi Sheng Wu Xue Bao. 2015;31(12):1267-1275. Epub 2015 Dec 23.
5
[Angiogenesis in patients with hematologic malignancies].[血液系统恶性肿瘤患者的血管生成]
Onkologie. 2001 Sep;24 Suppl 5:75-80. doi: 10.1159/000055192.
6
Angiogenesis and anti-angiogenesis in hematological malignancies.血液系统恶性肿瘤中的血管生成与抗血管生成
J Hematother Stem Cell Res. 2003 Feb;12(1):11-22. doi: 10.1089/152581603321210091.
7
Vascularity, angiogenesis and angiogenic factors in leukemias and myelodysplastic syndromes.白血病和骨髓增生异常综合征中的血管形成、血管生成及血管生成因子
Leuk Lymphoma. 2003 Feb;44(2):213-22. doi: 10.1080/1042819021000029777.
8
[Angiogenesis and hematological malignancies].[血管生成与血液系统恶性肿瘤]
Tidsskr Nor Laegeforen. 2003 Nov 20;123(22):3198-200.
9
Role of angiogenesis in chronic lymphocytic leukemia.血管生成在慢性淋巴细胞白血病中的作用。
Cancer. 2006 Sep 1;107(5):925-34. doi: 10.1002/cncr.22086.
10
Angiogenesis, angiogenic factor expression and hematological malignancies.血管生成、血管生成因子表达与血液系统恶性肿瘤
Anticancer Res. 2001 Nov-Dec;21(6B):4333-9.
引用本文的文献
1
Inflammation mediated angiogenesis in chronic lymphocytic leukemia.慢性淋巴细胞白血病中的炎症介导的血管生成。
Ann Hematol. 2024 Aug;103(8):2865-2875. doi: 10.1007/s00277-024-05781-1. Epub 2024 May 7.
2
The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways.骨髓微环境（BMM）细胞在急性髓系白血病（AML）进展中的作用：免疫检查点、代谢检查点和信号通路。
Cell Commun Signal. 2023 Sep 21;21(1):252. doi: 10.1186/s12964-023-01282-2.
3
Targeting PI3K/Akt signal transduction for cancer therapy.针对 PI3K/Akt 信号转导通路的癌症治疗策略。
Signal Transduct Target Ther. 2021 Dec 16;6(1):425. doi: 10.1038/s41392-021-00828-5.
4
Investigating the expression pattern of the angiopoietin-Tie system in ALL and its correlation with baseline characteristics.研究血管生成素-Tie系统在急性淋巴细胞白血病中的表达模式及其与基线特征的相关性。
Blood Res. 2021 Jun 30;56(2):79-85. doi: 10.5045/br.2021.2021024.
5
Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?磷酸肌醇 3-激酶信号通路在肿瘤微环境中的作用：在使用 PI3K 抑制剂治疗慢性淋巴细胞白血病时，我们需要考虑哪些因素？
Front Immunol. 2021 Jan 20;11:595818. doi: 10.3389/fimmu.2020.595818. eCollection 2020.
6
Modulating barriers of tumor microenvironment through nanocarrier systems for improved cancer immunotherapy: a review of current status and future perspective.通过纳米载体系统调节肿瘤微环境屏障以改善癌症免疫治疗：现状与未来展望的综述。
Drug Deliv. 2020 Dec;27(1):1248-1262. doi: 10.1080/10717544.2020.1809559.
7
Acute Myeloid Leukemia and the Bone Marrow Niche-Take a Closer Look.急性髓系白血病与骨髓微环境——深入探究
Front Oncol. 2018 Oct 12;8:444. doi: 10.3389/fonc.2018.00444. eCollection 2018.
8
Bone Marrow Blood Vessels: Normal and Neoplastic Niche.骨髓血管：正常与肿瘤微环境
Oncol Rev. 2016 Nov 24;10(2):306. doi: 10.4081/oncol.2016.306. eCollection 2016 Oct 10.
9
Post-transcriptional regulation of cytokine and growth factor signaling in cancer.癌症中细胞因子和生长因子信号传导的转录后调控
Cytokine Growth Factor Rev. 2017 Feb;33:83-93. doi: 10.1016/j.cytogfr.2016.11.004. Epub 2016 Dec 2.
本文引用的文献
1
Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.急性髓系白血病的表观遗传治疗：现状与未来方向
Semin Hematol. 2015 Jul;52(3):172-83. doi: 10.1053/j.seminhematol.2015.04.003. Epub 2015 Apr 8.
2
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.一项针对血液系统恶性肿瘤患者的1期剂量递增试验，该试验使用双重Aurora/VEGF受体激酶抑制剂伊洛拉塞替布。
Invest New Drugs. 2015 Aug;33(4):870-80. doi: 10.1007/s10637-015-0242-6. Epub 2015 May 2.
3
Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling.福瑞替尼通过降低VEGFR-2/3和TIE-2信号传导，在体内抑制胰腺癌的血管生成、淋巴管生成和肿瘤生长。
Oncotarget. 2015 Jun 20;6(17):14940-52. doi: 10.18632/oncotarget.3613.
4
Functional interaction between CTGF and FPRL1 regulates VEGF-A-induced angiogenesis.结缔组织生长因子（CTGF）与甲酰肽受体样1（FPRL1）之间的功能相互作用调节血管内皮生长因子A（VEGF-A）诱导的血管生成。
Cell Signal. 2015 Jul;27(7):1439-48. doi: 10.1016/j.cellsig.2015.04.001. Epub 2015 Apr 9.
5
Social defeat stress promotes tumor growth and angiogenesis by upregulating vascular endothelial growth factor/extracellular signal-regulated kinase/matrix metalloproteinase signaling in a mouse model of lung carcinoma.在肺癌小鼠模型中，社会挫败应激通过上调血管内皮生长因子/细胞外信号调节激酶/基质金属蛋白酶信号通路促进肿瘤生长和血管生成。
Mol Med Rep. 2015 Jul;12(1):1405-12. doi: 10.3892/mmr.2015.3559. Epub 2015 Mar 27.
6
Identification of a novel E-box binding pyrrole-imidazole polyamide inhibiting MYC-driven cell proliferation.一种新型E盒结合吡咯-咪唑聚酰胺抑制MYC驱动的细胞增殖的鉴定。
Cancer Sci. 2015 Apr;106(4):421-9. doi: 10.1111/cas.12610. Epub 2015 Mar 3.
7
Angiogenesis in myeloproliferative neoplasms, new markers and future directions.骨髓增殖性肿瘤中的血管生成、新标志物及未来方向。
Memo. 2014;7:206-210. doi: 10.1007/s12254-014-0142-z. Epub 2014 May 22.
8
Heparan sulfate D-glucosaminyl 3-O-sulfotransferase-3B1 (HS3ST3B1) promotes angiogenesis and proliferation by induction of VEGF in acute myeloid leukemia cells.硫酸乙酰肝素D-葡糖胺基3-O-磺基转移酶-3B1（HS3ST3B1）通过诱导急性髓系白血病细胞中的血管内皮生长因子（VEGF）来促进血管生成和增殖。
J Cell Biochem. 2015 Jun;116(6):1101-12. doi: 10.1002/jcb.25066.
9
Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.抗血管生成策略再探讨：从饿死肿瘤到缓解缺氧
Cancer Cell. 2014 Nov 10;26(5):605-22. doi: 10.1016/j.ccell.2014.10.006.
10
Angiogenic factors in chronic lymphocytic leukaemia (CLL): Where do we stand?慢性淋巴细胞白血病（CLL）中的血管生成因子：我们处于什么位置？
Crit Rev Oncol Hematol. 2015 Mar;93(3):225-36. doi: 10.1016/j.critrevonc.2014.10.007. Epub 2014 Oct 12.
Zotero 插件